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Effectiveness of a Multidisciplinary 
Patient Assistance Program in 
Diabetes Care  
Doyle E, Taveira T, Julian R, Cohen L, Monteith K 
 
Describing patient health outcomes at the Diabetes 
Resource Center at St. Joseph Health Services of 
Rhode Island 
 
 
Background 
Presently, there are over 23.6 million Americans with diabetes 
mellitus.7 Approximately 65% of people with diabetes mellitus die of 
cardiovascular disease,4 which is largely preventable by simultaneous 
control of multiple cardiovascular risk factors.5 It is estimated that 
nearly 21 million patients with diabetes are uninsured or 
underinsured.7 Patient assistance programs have been proposed to be 
an effective model to improved diabetes related outcomes through 
efficient use of resources, improvement of access to care, intensive 
medication up-titration and promotion of behavioral change through 
group support.9 However, little is known about the effectiveness of 
these types of programs in diabetes care. 
 
Abstract 
Objectives: The primary outcome for diabetes analysis is the 
change in hemoglobin A1C (HbA1c). This value describes the average 
glucose level in a patient’s blood stream over the preceding three 
months. Secondary outcomes will be changes in blood pressure, serum 
lipids, and patient body mass index.  
Study Design: This retrospective chart review is to evaluate the 
changes in personal health markers that serve as prognostic indicators 
in the progression of type 2 diabetes mellitus.  
Methods: Assessing electronic medical records of selected 
patients in the DRC database from baseline to a twelve-month follow-
up period can show how effective the Patient Assistance Liaison (PAL) 
program is. A statistical analysis of the data will be performed between 
the data sets of PAL Program patients and insured (non-PAL) patients 
to show significance. It is hoped that the data will serve as pilot data 
to determine if a prospective, randomized-controlled study should be 
performed to evaluate the efficacy of patient assistance program 
strategies in reducing the overall cardiovascular risk of patients with 
type 2 diabetes. Subjects in the PAL Program at the Diabetes Resource 
Center (DRC) of the St. Joseph Health Services of Rhode Island 
Hospital for Specialty Care have no health insurance to pay for needed 
services and medications. It is desirable to know if the care they are 
receiving is equivalent to patients at the DRC that have prescription 
drug insurance from a third party provider.  
Results: From baseline to follow-up, the PAL program patients 
experienced improvements in health that were equivalent to that of 
the non-PAL patient group. In the outcomes of total cholesterol and 
low-density lipoprotein cholesterol (LDL-C), the PAL group had 
statistically significant improvements that were not seen in the non-
PAL group. 
Conclusion: If properly managed and funded, a patient 
assistance program can be an effective outlet for patients with little or 
no resources. 
 
 
Introduction 
The patients seen at the Diabetes Resource Center (DRC) of the St. 
Joseph Health Services of Rhode Island are served to prevent 
cardiovascular disease and microvascular complications associated 
with uncontrolled diabetes and disease progression. It is beneficial to 
observe whether having health insurance can cause disparities in 
health care delivery at the DRC and influence overall outcomes in long-
term disease management.  The DRC Patient Assistance Liaison (PAL) 
Program enrolls patients without health insurance referred to the 
program from the Adult Primary Care clinic in the St. Joseph Health 
Services Hospital. The PAL program was initiated in July 2006 and has 
continued to grow.  To gauge the efforts of the program, an audit was 
conducted to assess the health status of the PAL patients.      
 
 
Research Design and Methods 
Study Design: 
This was a retrospective chart review of the electronic medical records 
of patients diagnosed with type 2 diabetes enrolled at the St. Joseph 
Health Services DRC from July 1, 2006 to March 31, 2007. There were 
assessments for medical history, systolic blood pressure (SBP), 
diastolic blood pressure (DBP), hemoglobin A1c (HbA1c), lipid profile, 
body mass index (BMI) and enrollment in the PAL program. This study 
resembled a cohort design.  
The University of Rhode Island’s Institutional Review Board in 
conjunction with the St. Joseph Health Services of Rhode Island 
approved this study. 
 A total of 199 patients were assessed to see if clinical significance 
exists in the care provided to the patients served at the DRC.  This 
care must meet national standards. The American Diabetes 
Association, American Heart Association, and the Seventh Report of 
the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure have set the guidelines 
employed.     
 
Inclusion Criteria: 
All patients eligible for inclusion  had to be at least 18 years of age 
with a chart documentation of type 2 diabetes mellitus in the St. 
Joseph Health Services DRC. Patients must be enrolled between July 1, 
2006 and March 31, 2007, and have documented follow-up visits 
twelve months after the original enrollment date. Subjects must have 
complete lipid profiles, blood pressures, HbA1c values, and body mass 
index measurements upon entry into the program and then 12 months 
after. Subjects must see a primary care provider at the St. Joseph 
Health Services of Rhode Island’s Adult Primary Care clinic and have a 
record in the electronic medical system of the DRC database. 
Exclusion criteria:  
Any patient who does not have baseline values for serum lipids, blood 
pressure, HbA1c or body mass index, as well as the corresponding 
values 12 months later. 
 
 
Diabetes Resource Center (DRC) Patients:  
Patients are referred to the DRC by primary care physicians in the 
Adult Primary Care clinic of the St. Joseph Health Services Hospital for 
Specialty Care, by outside primary care physicians or social service 
agencies, or are self-referred for case and diabetes management.  The 
DRC provides access to diabetes education, individualized primary care 
visits for diabetes and referral for specialty care services within the 
DRC. Specialty care services consist of consultation with Certified 
Diabetes Outpatient Educator (CDOE) nurses, pharmacists, 
nutritionists or visits with treatment specialists such as 
ophthalmologists and podiatrists, as well as enrollment into the PAL 
program to obtain free medication for their diabetes and related 
conditions.   
 
Patient education consists of six, one hour class sessions consistent 
with American Diabetes Association standards for self-management 
eduction.6 Visits with a primary care physician are held approximately 
every 3-4 months and last approximately 20 minutes.  Specialty visits 
can last up to one hour in length with the DRC CDOE nurses, 
pharmacists, nutritionists, ophthalmologists and podiatrists.  
 
 
PAL Program:  
Patients eligible for the PAL program were uninsured and were unable 
to pay for their medications for the treatment of diabetes or diabetes-
related conditions.  Under the supervision of a physician, the CDOE 
nurses were the primary providers in the DRC.  At the initial visit, 
nurses assessed medication adherence and laboratory parameters, and 
developed a treatment plan to control blood pressure, lipids and 
diabetes.  Options for smoking cessation were discussed when 
applicable. Individualized diet and exercise programs were also 
created, and referral to a nutritionist and physical therapist were made 
on an as-needed basis.  The Pharm.D. intern assisted with medication 
reconciliation and pharmacotherapeutic recommendations for the 
treatment of hypertension, hyperlipidemia, diabetes and tobacco 
cessation and made recommendations for therapeutic interchange 
based on the current availability of free medications in the clinic 
supply.  
 
 
Outcomes:  
The primary outcome is the change in HbA1c values, serum lipids and 
blood pressures in patients with diabetes enrolled in the PAL Program 
at the St. Joseph Health Services of Rhode Island Hospital for Specialty 
Care DRC after twelve months of enrollment.  
Secondary outcomes include the difference in national guideline 
adherence rates for serum lipids1, glycemic control2 and blood 
pressure3 between patients who are enrolled and those who are not 
enrolled in the PAL program at the  St. Joseph Health Services DRC 
after twelve months of the patient baseline date. Guideline adherence 
at twelve months will be defined as an HbA1c < 7%, SBP < 130mmHg, 
DBP <80mmHg, total cholesterol <200mg/dL, LDL-C <100mg/dL, 
HDL-C > 40mg/dL, and triglycerides < 150mg/dL. Recommendations 
for weight loss were given to all patients in the DRC when applicable. A 
successful outcome for BMI would therefore be classified as < 
30kg/m2. 
 
 
 
Statistical Analysis: 
Continuous variables will be expressed as mean ± SD, and categorical 
variables as percentages. We will use statistical software (SPSS 9.0 for 
Windows; SPSS, Inc., Chicago, Illinois) for data analysis. MANOVA with 
repeated measures will be used to compare the serum lipids, glycemic 
measures, blood pressure and BMI values at baseline and twelve 
months after enrollment in the St. Joseph Health Services DRC in both 
those enrolled in the PAL program and those not enrolled. Discriminant 
function analysis (DFA) can be used to determine the relationship 
between the demographic variables and change in dependent variables 
during treatment. Chi-square testing will be used to compare the 
frequency of patients that achieved American College of Cardiology / 
American Heart Association3 and American Diabetic Association7 
guideline recommended goals for the major cardiovascular risk factors 
at baseline and twelve months after. In order to detect the apparent 
effect of the PAL program vs. those not enrolled in PAL, we will repeat 
the above analyses by excluding those patients who were at target 
goals for individual risk factors at baseline. In addition, the change in 
weight will be reanalyzed in those patients with a baseline BMI > 
30kg/m2. Stepwise logistic regression modeling will be used to 
determine the predictors of improvement as defined as guideline 
adherence when patients met the therapeutic goal of SBP < 130 mm 
Hg, A1C < 7%, total cholesterol < 200 mg/dl and LDL Cholesterol < 
100 mg/dL.  All tests will be considered significant when 2-sided P is 
less than 0.05.  
 
Sample size calculations and power analysis: 
Based on preliminary data, a sample size of 170 would provide >90% 
power to detect a 10% difference between baseline values and 12 
months of follow-up in the DRC for each of the individual outcome 
measures: serum lipids, glycemic measures, and BMI values with a 
type I (alpha) error of <5%. The sample size was increased by 15% to 
account for potential missing data given that this was a retrospective 
analysis. 
 
 
 
Results 
Population: 
Patient demographics between July 1, 2006 and March 31, 2007 
 
 
 
 
 
 
 
   
Table 1. Baseline Characteristics  (n=199) 
Characteristic PAL Group 
n=93 
Non-PAL 
Group 
n=106 
P-value 
Age (Years) 
 
54.1±10.3 57.9±10.9 0.01 
Male 41.8 41.0 1.0 
Ethnicity 
         White 
         Hispanic 
         Black 
         Asian 
 
15.2 
64.1 
15.2 
5.4 
 
5.7 
77.1 
11.4 
5.7 
 
0.03 
0.06 
0.06 
0.93 
Body Mass Index 
(kg/m2) 
  
 
33.0±7.1 
 
 
33.3±6.8 
 
 
0.81 
Hypertension 61.3 67.9 0.37 
Hyperlipidemia 63.4 47.2 0.02 
Microvascular 
Complications 
        Neuropathy 
        Nephropathy 
        Retinopathy 
 
 
12.0 
4.4 
5.4 
 
 
21.9 
11.4 
3.0 
 
 
0.09 
0.11 
0.48 
Smoking Cessation 2.2 3.8 0.69 
Medication Utilization 
       Sulfonylurea  
       Metformin 
      Thiazolidinedione 
       Insulin 
       Aspirin 
       ACE-Inhibitor 
       Lipid Agent 
 
10.9 
10.9 
7.6 
4.4 
5.4 
6.5 
4.4 
 
15.2 
10.5 
17.3 
5.7 
13.6 
16.2 
11.4 
 
0.41 
         1.0 
0.05 
0.75 
 0.002 
0.04 
0.11 
 
 
Patients were similar at baseline from what the data indicate. 
Significance only existed for age, the white ethnicity, hyperlipidemia, 
aspirin and ACE-Inhibitor use. It is possible that more people were 
taking aspirin than as indicated here since it is easily available over-
the-counter.  
 
 
Twelve-month follow up in HbA1c were similar for the PAL and non-
PAL groups (8.1±1.9% v 8.1±2.0%, p=0.98), respectively. Total 
cholesterol values were statistically significant at baseline for the PAL-
group and the non-PAL group (184.2±37.5 v 167.2±39.9, p=0.0022), 
respectively, but were not statistically significant at the twelve-month 
follow-up period (169.3±36.7 v 169.9±44.6, p=0.9179). LDL-C values 
were significantly different at baseline for the PAL group and the non-
PAL group (110.1±34.1 v 97.4±33.5, p=0.0089), respectively. There 
was however, no difference at the twelve-month follow-up period 
(97.3±31.6 v 102.3±38.3, p=0.3227). BMI values were not different 
at baseline or follow-up for the PAL group and the non-PAL group 
(32.8±7.0 v 33.3±6.8, p=0.6697) and (34.0±7.1 v 33.3±6.2, 
p=0.6126), respectively (Table 2).  
 
Both PAL and non-PAL patients had similar adherence to guideline 
standards in the HbA1c values. At enrollment, 34.41% of PAL patients 
were at goal compared to 33.02% of non-PAL patients. At follow-up 
twelve months later, 35.48% of PAL patients were at goal, compared 
to 30.19% of non-PAL patients. There exists no statistical significance 
between these two groups in HbA1c values at follow-up (P=0.88). 
Significance did exist in the LDL-C values at baseline as 36.56% of PAL 
patients were at goal, compared to 52.83% of non-PAL patients 
(P=0.02). No statistical significance existed between the two groups at 
the follow-up period. There were 63.04% of PAL patients at goal, 
compared with 52.83% of non-PAL patients (P=0.15) (Figure 2).  
 
 
 
Discussion 
 
These data demonstrate that patients enrolled into a patient assistance 
program are able to achieve a similar level of HbA1c, blood pressure, 
lipids and BMI as insured patients. In the PAL Program, all patients 
were receiving the same standards of care, were given the same 
weight loss, blood pressure and lipid goals, reduction strategies, and 
received similar care for diabetes. Despite the similarities at baseline, 
and the equality of care provided to all patients, it appears that the 
PAL program patients experienced some significant reductions in 
cardiovascular risk that were not witnessed to the same extent for the 
patients not in the PAL group.  
 
The effectiveness of the multidisciplinary patient assistance model as 
assessed by changes in guideline adherences at the 12-month follow-
up show that significant progress can be made in individual patient 
health. Patients in the PAL program often started out below standard 
guidelines and experienced improvements in health that met national 
guidelines and were comparable to the non-PAL group.  This is 
attributed to increased access to care and free medications provided 
by grants and samples from pharmaceutical corporations.  This is 
encouraging as patient assistance programs are often difficult to enroll 
in, and can still end up draining a patient’s financial resources.  From 
the guideline adherence rates and actual patient values, having health 
insurance did not cause disparities in patient health. 
This is important because many patient assistance programs exist but 
there is little data substantiating their effectiveness.  
 
Intriguing are the trends of the HbA1c values over the 12-month 
duration for the separate categories. While the non-PAL patient values 
went up, the average values for the PAL program patients decreased 
from baseline. As diabetes care is a primary concern for the DRC, and 
diabetes itself is an independent cardiovascular risk factor, guidelines 
recommend tight blood glucose control to maintain overall health.  
Other important improvements occurred in HbA1c values.  Although 
some patients, particularly in the PAL program, did not achieve a value 
under 7%, there were still significant reductions.  Many patients had 
poor disease control before entrance into the program. Some patients 
started at HbA1c values over 12%, and achieved a value under 10%.  
This would still qualify as a positive difference, and this is important 
for a patient to know.  For this analysis, we employed national 
guidelines, and further information about all patients that had HbA1c 
values decline is not provided in this discussion.        
 
Most notable are the results from the LDL-C, triglyceride and total 
cholesterol analyses. Patients in the PAL program achieved a 
statistically significant reduction while the majority of insured patients 
stayed the same or worsened. The lipid values are broken up into total 
and LDL cholesterol values, which are the two main independent risk 
factors for atherosclerotic vascular events in diabetic patients. In the 
LDL-C category, the PAL group had a statistically significant reduction, 
which is demonstrated by the guideline adherence rate and the 
comparative analysis with the non-PAL group. Triglycerides are 
important to assess as well since they serve as an objective measure 
of circulating fatty acids.  While the non-PAL patients had slightly 
better outcomes in triglycerides, the differences are not statistically 
significant. 
 
Study limitations include a single site program. Nonetheless the results 
demonstrate the effectiveness of a PAL program to manage a 
population with multiple comorbidities that traditionally is considered 
difficult to treat. A second limitation is that there is only a twelve-
month follow-up period, and it is difficult to know if effectiveness can 
be maintained over longer periods of time. Third, given the training 
and experience of the PAL providers, it is uncertain whether the 
success of this model can be easily reproduced through another PAL 
team with different training and experience. Further, randomized-
controlled trials with a different team of providers of different 
experiences and in other institutions would be necessary to assess the 
generalizability of the PAL model. Finally, there is no cost-assessment 
of the PAL Program, as costs were not formally tracked. However, a 
simple cost estimation associated with the program can be attempted 
by including personnel salaries, facility costs, medication supplies, and 
laboratory costs per participant. The cost for the personnel in this 
program was calculated using the hourly rate for time required by each 
provider for preparation, intervention and documentation. The hourly 
rate was calculated using the annual salaries of providers from the 
official job site for the United States Federal Government 
(www.usajobs.gov) by July, 2008. Facility costs were estimated by 
including the cost for support staff, space, electricity, mail, fax and 
telephones. Laboratory costs included the cost for a chem-7, lipid 
panel and HbA1c tests ordered at baseline and 12-month follow-up.  
These added for a total of $49.23 per patient per hour. It is reasonable 
to assume that the control of cardiovascular risk factors may reduce 
long-term costs via reduction of acute care visits, hospitalization and 
diabetes related complications.  
 
 
 
Conclusion: 
This study suggests that a PAL program model is feasible and effective 
for improving multiple cardiac risk factors in patients with type 2 
diabetes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Appendix: 
Figure 1. Patient Selection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Adult Primary Care 
Clinic Registries 
n=6020 
Active Diagnosis of 
Diabetes Mellitus Type 2 
n=373 
Citations of Diabetic 
Patients Without Health 
Insurance 
n=131 
Patients with Record of 
Office Visit 12 Months 
After Enrollment Date 
n=93 
Citations of Diabetic 
Patients With Health 
Insurance 
n=242 
Patients with Record of 
Office Visit 12 months 
After Baseline Date 
n=106 
  
Table 2. Baseline to Follow-Up Value and Average Change  
P-value for Total Cholesterol Parameter=0.0023 
P-value for LDL-C Parameter=0.0015 
 
 PAL Group   Non-PAL 
Group 
  
 N=93   N=106   
Parameters Baseline 12 Months Average 
Change 
Baseline 12 Months Average 
Change 
HbA1c (%± SD) 8.3 ± 2.2 8.1 ± 1.9  -0.2 ± 1.7 8.2 ± 2.0  8.1 ±2.0 -0.1 ± 1.4 
 
SBP (mmHg ± SD) 
136.7 ± 21.1 133.6 ± 17.1 -3.3 ± 20.7  139.1 ± 20.1 134.3 ± 
20.7 
-4.8 ± 22.2 
 
DBP (mmHg ± SD) 
81.3 ± 10.9  78.7 ± 9.2  -2.5 ± 11.1  79.4 ± 11.0  77.1 ± 10.4  -2.3 ± 12.7 
Total Cholesterol 
(mg/dL± SD) 
184.2 ± 37.5  169.3 ± 36.7  -15.7 ± 45.3* 167.2 ± 39.9 169.9 ± 
44.6 
2.7 ± 37.7 
LDL-C  (mg/dL± SD) 110.1 ± 34.1  97.3 ± 31.6  -13.4 ± 41.9*  97.4 ± 33.5 102.3 ± 
38.3 
4.9 ± 37.2  
HDL-C (mg/dL ± SD) 45.6 ± 12.4 44.8 ± 12.1 -0.7 ± 12.2 45.0 ± 13.9 42.0 ± 12.0 -3.0 ± 12.5 
Triglycerides    
(mg/dL ± SD) 
145.9 ± 104.8 128.9 ± 74.9 -18.2 ± 109.4 122.2 ± 72.8 128.7 ± 
73.1 
6.5 ± 68.0 
BMI (kg/m2 ± SD) 32.8 ± 7.0 34.0 ± 7.1 1.1 ± 4.3  33.3 ± 6.8 33.3 ± 6.2 0.2 ± 2.7  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2. Guideline Adherence of Baseline and Follow-Up Analysis 
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